Leadership History

Johnson & Johnson: CEO History

5 leaders · 1932 to present

Company Overview

Johnson & Johnson began as a medical-products company in the nineteenth century and became a diversified healthcare giant. After the Kenvue separation it is a more focused healthcare company centered on medicine and medical technology.

5

Joaquin Duato

Chairman and Chief Executive Officer

2022 – Present

4 years (current)

Key Decisions & Impact

Duato became CEO in January 2022 and added the chairman title later that year, then led completion of the Kenvue consumer-health separation in 2023, the largest structural change to J&J's business in decades. Since then he has directed capital toward large MedTech and pharmaceutical acquisitions, including Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025), while managing the company's ongoing talc-litigation liability.

Legacy

Under Duato, J&J's post-Kenvue revenue reached $94.193 billion in FY2025 with $26.804 billion in net earnings, split roughly 64% Innovative Medicine and 36% MedTech, both segments growing about 6% year over year -- early evidence that the narrower two-segment focus is translating into consistent growth across both halves of the business. Analysts frequently cite the post-Kenvue margin expansion as validation of the narrower two-segment strategy he inherited and completed.

4

Alex Gorsky

Former Chairman and Chief Executive Officer

2012 – 2022

10 years

Key Decisions & Impact

Gorsky became CEO in 2012, succeeding Weldon amid a period of manufacturing-quality recalls, and worked to restore J&J's operational reputation while continuing to expand the pharmaceutical and MedTech portfolio through the COVID-19 pandemic, when J&J developed a single-dose COVID-19 vaccine. He also began laying the groundwork for separating the consumer-health business from the higher-margin medicine and device operations.

Legacy

Gorsky's tenure set up the 2023 Kenvue separation that completed under his successor, repositioning J&J around the Innovative Medicine and MedTech structure the company still uses today, while navigating COVID-era demand swings and ongoing talc-related litigation. He also managed the company through the early stages of talc-related litigation that continued to affect J&J's legal costs well after his 2022 departure. J&J single-dose COVID-19 vaccine, developed under his leadership, was authorized for emergency use in 2021. He also expanded J&J international manufacturing capacity substantially during his tenure to support pandemic-era vaccine production at scale.

3

William Weldon

Former Chairman and Chief Executive Officer

2002 – 2012

10 years

Key Decisions & Impact

Weldon became CEO in 2002 and continued J&J's acquisition strategy, notably buying Pfizer's consumer-health division in 2006 for its Listerine and other over-the-counter brands, while steering the company through the 2008 financial crisis without major disruption to its business.

Legacy

Weldon's later years as CEO were overshadowed by a wave of product recalls -- including Tylenol and Motrin products pulled for manufacturing-quality problems -- and corruption-related charges that damaged J&J's reputation for the operational discipline built under his predecessors, a contrast to the Credo-driven crisis response the company was known for in 1982. He retired in 2012 under pressure from the board after a string of manufacturing-related recalls damaged the company's quality reputation, a legacy his successor Alex Gorsky spent years repairing. His acquisition of Pfizers consumer division for Listerine and other brands in 2006 remains one of the larger deals of his tenure. The board statement announcing his exit publicly praised his decade of stewardship even as it acknowledged the need for a change in direction.

2

Ralph Larsen

Former Chairman and Chief Executive Officer

1989 – 2002

13 years

Key Decisions & Impact

Larsen became CEO in 1989 after helping build Tylenol into a blockbuster in the late 1970s, when he was part of the team that grew its sales from $70 million to $500 million within a decade. As CEO, he spent $21.7 billion acquiring more than 40 companies, including Neutrogena, Kodak's clinical-diagnostics business, Cordis, and Centocor, while cutting roughly $2 billion in annual operating costs between 1994 and 1999 and expanding into Russia and Eastern Europe.

Legacy

Larsen's acquisition-led growth strategy diversified J&J well beyond its consumer and pharmaceutical roots into diagnostics and medical devices, laying groundwork for the MedTech segment that generates more than a third of company revenue today, and he delivered a run of 25% shareholder returns during his 13-year tenure. His acquisitions remain some of the most-cited examples of successful large-scale healthcare M&A from the 1990s. Larsen retirement in 2002 marked the end of an era defined by aggressive, successful large-scale acquisitions rather than organic-only growth.

1

Robert Wood Johnson II

Chairman

1932 – 1963

31 years

Key Decisions & Impact

Johnson, son of co-founder Robert Wood Johnson, became chairman in 1932 and in 1943 authored 'Our Credo,' an one-page statement of responsibility to customers, employees, communities, and shareholders -- in that order -- that remains J&J's official governing philosophy more than 80 years later. He guided the company's transformation from a family-owned New Jersey manufacturer into a global corporation, expanding through World War II and the postwar baby boom.

Legacy

Under Johnson's three decades as chairman, J&J's revenue grew more than fifteenfold, and Our Credo became the reference point invoked in 1982 to justify J&J's widely praised nationwide Tylenol recall -- a direct application of the Credo's stated priority of customer safety over short-term profit. Business historians frequently cite Our Credo as an early example of stakeholder-capitalism thinking, decades before the term became common. His Credo remains posted in J&J facilities worldwide as a daily operating reference for employees.

Challenges & Strategic Context

Johnson & Johnson faces patent expirations, biosimilar pressure, drug pricing scrutiny, product litigation, regulatory risk, R&D productivity demands, and MedTech competition.

Johnson & Johnson CEO and Leadership FAQ

Who is the current chief executive officer of Johnson & Johnson?

Joaquin Duato currently leads Johnson & Johnson, overseeing strategic vision, balance sheet health, and organizational execution in Healthcare and Pharmaceuticals.

What is the CEO's primary strategic agenda for 2026?

Under executive direction, Johnson & Johnson is prioritizing workflow automation alongside disciplined capital allocation to maximize shareholder value.

How has executive leadership guided Johnson & Johnson through past market transitions?

Leadership at Johnson & Johnson has historically navigated industry cycles by restructuring operational priorities and expanding competitive moats.